Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Peripheral Artery Disease I: Introduction

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is slower than the...

Anaphase Promoting Complex

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...

Huntington Disease l: Introduction

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Dopamine-responsive post-anoxic parkinsonism.

Journal of Parkinson's disease·2025

Same author

Primary Progressive Apraxia of Speech Caused by TDP-43: A Case Report.

Neurology. Genetics·2024

Same author

Parkinson's disease progression is multifaceted: Evidence for the underlying benchmarks.

Parkinsonism & related disorders·2024

Same author

Tenascin-R Autoimmunity: Isolated Tremor Reversed with Immunotherapy.

Annals of neurology·2023

Same author

Levodopa, homocysteine and Parkinson's disease: What's the problem?

Parkinsonism & related disorders·2023

Same author

Lifelong constipation in Parkinson's disease and other clinically defined alpha-synucleinopathies: A population-based study in Southeast Minnesota.

Parkinsonism & related disorders·2023

Search research articles

Related Experiment Video

Updated: Jun 28, 2026

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

Antiphospholipid antibody-associated chorea.

Nicole M Orzechowski¹, Alexandra P Wolanskyj, J Eric Ahlskog

¹Division of Rheumatology, Department of Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA. nicoleorzechowski@msn.com

The Journal of Rheumatology

|October 18, 2008

Summary

This summary is machine-generated.

Antiphospholipid antibody-associated chorea typically affects women and is mild to moderate. Treatment is effective, but anticoagulation is only recommended for thrombosis, not chorea alone, due to bleeding risks.

Related Experiment Videos

Last Updated: Jun 28, 2026

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets

Published on: February 10, 2020

Area of Science:

Neurology
Rheumatology
Immunology

Background:

Antiphospholipid antibodies (aPL) are associated with various neurological disorders.
Chorea is a hyperkinetic movement disorder that can be linked to autoimmune conditions.

Purpose of the Study:

To characterize the clinical presentation, management strategies, and outcomes for patients experiencing chorea due to antiphospholipid antibodies (aPL).

Main Methods:

A retrospective analysis of patients diagnosed with chorea and aPL between 1990 and 2005.
Clinical data, including demographics, associated conditions (e.g., systemic lupus erythematosus), antibody profiles, treatments, and outcomes, were reviewed.

Main Results:

Eighteen patients were identified; 4 had systemic lupus erythematosus (SLE). Non-SLE patients had more thrombotic events and pregnancy losses than SLE patients.
Chorea was generally bilateral and mild to moderate. All patients responded to treatment, with immunosuppression and antidopaminergic agents being common therapies.
Anticoagulation was used for thrombosis, but two non-SLE patients died from bleeding complications. IgM anticardiolipin antibodies (aCL) were prevalent in non-APS patients with chorea.

Conclusions:

aPL-associated chorea predominantly affects women with mild to moderate symptoms, irrespective of SLE status.
Anticoagulation should be reserved for established thrombosis in aPL-positive patients due to significant bleeding risks.
IgM aCL may play a crucial role in the pathogenesis of chorea in the absence of antiphospholipid antibody syndrome (APS).